ライフサイエンスコーパス: adverse outcome

1 elatonin and polo-like kinase in babies with adverse outcome.

2 = 0.009) were independently associated with adverse outcome.

3 developing neonatal encephalopathy (NE) and adverse outcome.

4 ) and was associated with disease burden and adverse outcome.

5 sult (P = 0.02) were higher in neonates with adverse outcome.

6 ic cCMV there are currently no predictors of adverse outcome.

7 that was associated with lower risk for any adverse outcome.

8 independent value over RWMA in predicting an adverse outcome.

9 residual disease detection, associated with adverse outcome.

10 for frail than for robust patients for each adverse outcome.

11 Eighteen patients (34%) had an adverse outcome.

12 antibody-mediated rejection, and portend an adverse outcome.

13 -year-old man was admitted with pneumonia of adverse outcome.

14 cation and likelihood of a lesion to predict adverse outcome.

15 nia criteria, 8.6% (189/2199) experienced an adverse outcome.

16 rkers at clinical presentation to the ED for adverse outcome.

17 es the extent of LVAD infection and predicts adverse outcome.

18 %), and LV systolic dysfunction predicted an adverse outcome.

19 itical illness factors associated with these adverse outcomes.

20 identified in 7 studies (n = 3458) reporting adverse outcomes.

21 GFR; one-third progress to CKD, resulting in adverse outcomes.

22 ve broad-spectrum antibiotics and experience adverse outcomes.

23 itiated deliveries, and to prevent perinatal adverse outcomes.

24 nic obesity was also associated with LOS and adverse outcomes.

25 with an increased relative risk for serious adverse outcomes.

26 nate potential (CHIP) and is associated with adverse outcomes.

27 cal ventilation and has been associated with adverse outcomes.

28 al regulation of TH signaling and associated adverse outcomes.

29 pressive tumour phenotype has been linked to adverse outcomes.

30 Close postoperative monitoring may mitigate adverse outcomes.

31 elated manifestations that predict long-term adverse outcomes.

32 thyroxine could reduce the incidence of such adverse outcomes.

33 ng this at-risk population can help mitigate adverse outcomes.

34 tients is at risk of disease progression and adverse outcomes.

35 ic hypertension each independently predicted adverse outcomes.

36 with immunosuppressant pharmacokinetics and adverse outcomes.

37 diastolic blood pressure) within 6 h with no adverse outcomes.

38 quent in ICU patients and is associated with adverse outcomes.

39 plications, including preeclampsia and fetal adverse outcomes.

40 regarding the most informative predictors of adverse outcomes.

41 ach reduced subsequent maternal or perinatal adverse outcomes.

42 rohumoral inhibition have documented reduced adverse outcomes.

43 ression of disease, and mitigate the risk of adverse outcomes.

44 with childhood respiratory disease and other adverse outcomes.

45 nst women is associated with a wide range of adverse outcomes.

46 ure drugs to manage these symptoms and avoid adverse outcomes.

47 esis that differentiation is associated with adverse outcomes.

48 tic variants which are associated with these adverse outcomes.

49 estimate the risk of frailty associated with adverse outcomes.

50 for transplant and are at increased risk of adverse outcomes.

51 ance as these are associated with a range of adverse outcomes.

52 ach has not yet been developed for noncancer adverse outcomes.

53 is associated with bacterial coinfection and adverse outcomes.

54 present an opportunity to minimize long-term adverse outcomes.

55 0 mg/d, was associated with greater risk for adverse outcomes.

56 another, is of concern because of potential adverse outcomes.

57 lowing surgery is common and associated with adverse outcomes.

58 n for a range of serious fatal and non-fatal adverse outcomes.

59 am provides independent prognostic value for adverse outcomes.

60 idity) during aging are associated with many adverse outcomes.

61 nts and to identify elements contributing to adverse outcomes.

62 naling and Ca(2+) handling and often lead to adverse outcomes.

63 ampsia and associated maternal and perinatal adverse outcomes.

64 haly (PM and DM) had similarly high rates of adverse outcomes.

65 lead to widespread transmission and serious adverse outcomes.

66 al infarction (STEMI) and is associated with adverse outcomes.

67 product, and patient factors in the role of adverse outcomes.

68 botype 027 associate with severe disease and adverse outcomes.

69 but those with an unfavorable CTP had higher adverse outcomes.

70 y, is associated with known risk factors for adverse outcomes.

71 experiences (ACEs) is a risk factor for many adverse outcomes.

72 with IDSA severity, but not with subsequent adverse outcomes.

73 vice (AMA) discharge is common and linked to adverse outcomes.

74 elivery and expansion and is associated with adverse outcomes.

75 hy estimated glomerular filtration rate with adverse outcomes.

76 lysis estimated risk ratios for maternal and adverse outcomes.

77 pid-rich plaque (LRP) may be associated with adverse outcomes.

78 nt relationship, and caregiving itself, with adverse outcomes.

79 lar block), which carries increased risk for adverse outcomes.

80 tic pathways of effect, and monitoring early adverse outcomes.

81 en noted (n = 156, 53.4%) as contributing to adverse outcomes.

82 early identification of patients at risk for adverse outcomes.

83 es and recipients, they were associated with adverse outcomes.

84 er follow-up testing reduces therapy-related adverse outcomes.

85 mia in pregnancy are associated with risk of adverse outcomes.

86 e associated with increased risk of post-PCI adverse outcomes.

87 posing of trials to prevent, treat or reduce adverse outcomes.

88 In older adults, AML confers an adverse outcome(1,2).

89 was no evidence of a difference in perinatal adverse outcomes (15% vs 14%, 1.45, 0.73-2.90) or gestat

90 e no differences in adjusted 1-year risks of adverse outcomes across hospital quartiles of potent P2Y

91 ating apo M is independently associated with adverse outcomes across the spectrum of human heart fail

92 n commonly used childbirth interventions and adverse outcomes, adjusted for population characteristic

93 Frailty has long-term effect on each adverse outcome after discharge, rather than the effect

94 Long-term cognitive decline is an adverse outcome after major surgery associated with incr

95 study, 3.8% (n = 1243) experienced a severe adverse outcome after the procedure.

96 of sedative-hypnotics increases the risk of adverse outcomes after common surgical procedures.

97 identify CT and TEE biomarkers that predict adverse outcomes after IE surgery, adjusting for EuroSCO

98 ophageal echocardiography (TEE) findings and adverse outcomes after IE surgery.

99 CT and TEE features that predicted separate adverse outcomes after IE surgery.

100 en operator procedural volume and short-term adverse outcomes after percutaneous coronary interventio

101 t size, microvascular obstruction (MVO), and adverse outcomes after STEMI.

102 tive benzodiazepines and Z-drug receipt with adverse outcomes after surgery is unknown.

103 common and associated with increased odds of adverse outcomes after surgery, particularly when copres

104 action (LVEF) is an independent predictor of adverse outcomes after transcatheter aortic valve replac

105 not at higher risk for endocarditis or other adverse outcomes after TTVR, and endocarditis occurred w

106 Persistent smoking may cause adverse outcomes among patients with cancer.

107 variants were most strongly associated with adverse outcomes among patients without extra-cardiac an

108 e highly sensitive to identify patients with adverse outcome and could serve as early triage tools.

109 s in order to find new prognostic factors of adverse outcome and mortality.

110 e fraction (ECV) was predictive of composite adverse outcome and subsequent HF (all p < 0.001).

111 s are highly susceptible to COVID-19-induced adverse outcomes and complications.

112 ring pregnancy may lead to increased risk of adverse outcomes and conditions.

113 Adverse outcomes and costs were higher in the Impella er

114 with higher Impella use had higher rates of adverse outcomes and costs.

115 frailty and frailty is essential for prevent adverse outcomes and improving the overall health of old

116 ing indices significantly predicts composite adverse outcomes and subsequent HF in patients with AF a

117 visceral adiposity index was associated with adverse outcomes and, despite an overall correlation wit

118 ugh rare, leaflet thrombosis is an important adverse outcome, and further study is necessary to deter

119 aregiving, identified caregivers at risk for adverse outcomes, and evaluated a wide range of interven

120 given the relatively rare incidence of these adverse outcomes, any clinical trial would be challengin

121 cancer-associated risk factors for COVID-19 adverse outcomes are not fully characterized.

122 ding studies in childhood epilepsy, the only adverse outcome associated with CBD treatment was diarrh

123 prove maternal quality of life and limit the adverse outcomes associated with HG.

124 We found no differences in adverse outcomes associated with HIV infection for hospi

125 factor 6 (ATF6) arm of the UPR in mitigating adverse outcomes associated with ischemia/reperfusion (I

126 D, and the secondary aim was to identify the adverse outcomes associated with the occurrence of SSI.

127 Patterns, predictors, and post-KT adverse outcomes associated with these changes are uncle

128 phic characteristics and the presence of the adverse outcomes at baseline.

129 ger door-to-balloon delay and higher risk of adverse outcomes at the population level.

130 haly (PM and DM) had similarly high rates of adverse outcomes but showed improvement in growth measur

131 c inpatients are at elevated risk of serious adverse outcomes, but no previous study has comprehensiv

132 tion rates, without subsequent reductions in adverse outcomes, can indicate overuse.

133 While SGA infants had lower rates of adverse outcomes compared to those with microcephaly, no

134 VMI was found to be a stronger predictor for adverse outcomes compared with current well-established

135 While SGA infants had fewer adverse outcomes compared with microcephaly infants, not

136 ed with higher early and late mortality, and adverse outcomes compared with patients without renal di

137 ciated with increased periprocedural or late adverse outcomes compared with those without significant

138 nted, we found a lower incidence of maternal adverse outcomes, consistent with adoption of targeted,

139 endent association between AC after TAVR and adverse outcomes (death, p = 0.15; rehospitalization, p

140 Adverse outcomes detected in the reproductive system of

141 teristic assessed at follow-up, the risk for adverse outcomes differed significantly between the seve

142 g subgroups of recipients at higher risk for adverse outcomes due to hyperfiltration: African America

143 g subgroups of recipients at higher risk for adverse outcomes due to hyperfiltration: African America

144 Childhood hypertension can result in adverse outcomes during adulthood; identifying and treat

145 ncrease was accompanied by reductions in all adverse outcomes, except major amputations.

146 Increases in all-cause adverse outcome (excluding asthma)-associated HCRU and c

147 Capsular contracture is a common adverse outcome following implant breast reconstruction,

148 pants in the PRESERVE (Prevention of Serious Adverse Outcomes Following Angiography) trial with compr

149 e relative risk for and incidence of serious adverse outcomes following the development of CA-AKI and

150 an predict the probability or severity of an adverse outcome for a given magnitude of chemical intera

151 We calculated the odds of adverse outcome for each ten-unit increase in baseline s

152 atistically modeling the relative risk of an adverse outcome for thousands of subjects in The Cancer

153 ve of duration or dosage, is associated with adverse outcomes for patients with asthma, the longitudi

154 Preeclampsia leads to adverse outcomes for pregnant women.

155 ay lead to higher rates of complications and adverse outcomes for some groups.

156 oendocrine marker profiles do not predict an adverse outcome from RLT.

157 with higher risk of disease progression and adverse outcomes from coronavirus disease 2019 (COVID-19

158 t they are at a higher risk for infection or adverse outcomes from severe acute respiratory syndrome

159 tural heart disease are at increased risk of adverse outcomes from the coronavirus disease-2019 (COVI

160 ifferentially expressed between the good and adverse outcome groups, of which RGS1 and SMC4 were the

161 Overburdened systems and concerns of adverse outcomes have resulted in deferred cancer surger

162 CV was an independent predictor of composite adverse outcome (hazard ratio (HR): 1.258, 95% confidenc

163 he longitudinal effects of this treatment on adverse outcomes, healthcare resource utilization (HCRU)

164 s having increased risk for COVID-19 and its adverse outcomes, highlighting the need to screen and tr

165 Preterm delivery results in adverse outcomes; identifying and treating bacterial vag

166 inical association of hyperglycaemia with an adverse outcome in ACS.

167 V dysfunction is associated with the risk of adverse outcome in asphyxiated patients with HIE undergo

168 Adverse outcome in infarcted MyS3KO mice was associated

169 PGC-1alpha expression was associated with an adverse outcome in the TCGA glioblastoma dataset.

170 e temporal changes in medical prevention and adverse outcomes in a national cohort of patients with s

171 linical trials involving Ixekizumab revealed adverse outcomes in a small cluster of patients with IBD

172 y, we estimated the accumulation of multiple adverse outcomes in both groups.

173 ted prevalence of 50% and is associated with adverse outcomes in both mothers and offspring.

174 Obesity may contribute to adverse outcomes in coronavirus disease 2019 (COVID-19).

175 t failure (HF) are likely at higher risk for adverse outcomes in coronavirus disease-2019 (COVID-19),

176 y embolism, represent an important source of adverse outcomes in coronavirus disease-2019 (COVID-19).

177 Key myocardial processes that lead to adverse outcomes in FD include storage, hypertrophy, inf

178 The DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) trial disclosed DAPA'

179 PA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure), dapagliflozin, added

180 ensal anaerobic bacteria are associated with adverse outcomes in hematopoietic cell transplantation (

181 ment is associated with an increased risk of adverse outcomes in hospitalised older people with an un

182 evelopment, cognitive impairments, and other adverse outcomes in humans and wildlife.

183 on-appears to be an important determinant of adverse outcomes in LVNC patients.

184 s, even below the 99(th) percentile, predict adverse outcomes in patients and the general population.

185 either biomarker predicts the risk of major adverse outcomes in patients treated with angiotensin re

186 on, or valve operation) is a risk factor for adverse outcomes in patients undergoing Fontan palliatio

187 ological deficit (DIND) is a major driver of adverse outcomes in patients with aneurysmal subarachnoi

188 This effect has included the adverse outcomes in patients with cancer who develop COV

189 radiodensity (SMD) have been associated with adverse outcomes in patients with colorectal cancer (CRC

190 s 1p and 16q (LOH1p/16q) was associated with adverse outcomes in patients with favorable histology Wi

191 the evidence linking various types of ICR to adverse outcomes in patients with multivessel disease an

192 work index (LVSWI) has been associated with adverse outcomes in several populations of patients with

193 rs should be aware of the increased risk for adverse outcomes in sexual minority adolescents.

194 ne replacement in mitigating the burden from adverse outcomes in survivors.

195 rmality can identify those at higher risk of adverse outcomes in the absence of significant CAD.

196 They are at high risk of adverse outcomes in the first year of life.

197 They are at high risk of adverse outcomes in the first year of life.Antenatal Zik

198 The two groups with the best evidence of adverse outcomes in the setting of untreated asymptomati

199 nd was not associated with increased risk of adverse outcomes in the subsequent pregnancy.

200 Sarcopenia is a main indicator of adverse outcomes in this population, including poor qual

201 last growth factor 23 [FGF23]) contribute to adverse outcomes in this population.

202 delineate the relationship between falls and adverse outcomes in transplant and reduce the incidence

203 ologic neurologic signs were associated with adverse outcomes in univariable models.

204 PA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) showed that dapaglifl

205 PA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure), the sodium-glucose c

206 PA-HF trial (Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure).

207 Primary adverse outcomes included all-cause emergency department

208 d function that is associated with increased adverse outcomes including falls, functional decline, fr

209 eristics may contribute to susceptibility to adverse outcomes including sepsis and septic shock.

210 that result in decreased quality of life and adverse outcomes, including addictions, violence, and su

211 n observed, with RG and RGED associated with adverse outcomes, including COPD.

212 t was not associated with lower rates of any adverse outcomes, including death, readmission, emergenc

213 This contributes to a number of adverse outcomes, including diversion of leftover pills

214 frailty places a person at increased risk of adverse outcomes, including falls, hospitalisation, and

215 proportion of colonized people develop more adverse outcomes, including gastric ulcer disease, gastr

216 CHIP is associated with a variety of adverse outcomes, including haematological cancer and de

217 Adverse outcomes, including memory disturbances, are typ

218 A REMS program to reduce the risk of adverse outcomes, including misuse, abuse, addiction, an

219 d fibrosis are at markedly increased risk of adverse outcomes, including overall mortality, and liver

220 tially reduces the number of deaths or other adverse outcomes incurred during a trial.

221 nk between short interpregnancy interval and adverse outcomes is causal or is confounded by factors s

222 gical trends relate and disease severity and adverse outcomes is incompletely understood.

223 However, the absolute risk of adverse outcomes is small for either delivery approach.

224 entify the encephalopathic babies at risk of adverse outcome may accelerate the development of neurop

225 rapies is a mainstay of treatment to prevent adverse outcomes; nevertheless, patients with PAD are of

226 sociations between psychiatric disorders and adverse outcomes occur through broad psychological dimen

227 Overall, any adverse outcome occurred in 37.2% (n = 73 161) of women,

228 Adverse outcome occurred in 39 patients (11 deaths, 28 I

229 Absolute risk of at least one adverse outcome occurring within this timeframe were hig

230 persistent worsening frailty is an important adverse outcome of acute illness.

231 The primary endpoint was a composite adverse outcome of cardiac death, subsequent HF or strok

232 s on the rise contributing to concerns about adverse outcomes of co-exposure to saccharin and nicotin

233 le with psoriasis may confer greater risk of adverse outcomes of coronavirus disease 2019 (COVID-19),

234 hronic fetal hypoxia, one of the most common adverse outcomes of human pregnancy complicated by fetal

235 ns at 26 weeks gestation are associated with adverse outcomes of pregnancy and establish whether thes

236 Three patients had adverse outcomes or complications, with only one (0.3%)

237 ymph nodes was significantly associated with adverse outcome (P = 0.001 for nodal SUV above vs below

238 h nodes was significantly associated with an adverse outcome (P = 0.001 for nodal SUV above vs. below

239 We provide an example of how the adverse outcome pathway (AOP) framework and associated d

240 The Aggregate Exposure Pathway (AEP) and Adverse Outcome Pathway (AOP) frameworks can mechanistic

241 We present an adverse outcome pathway (AOP) network to link data deriv

242 al toxicity and beyond is crucial within the adverse outcome pathway concept and the 3R framework.

243 We propose an adverse outcome pathway, where the oxidation of metaboli

244 gene expression changes suggest a potential adverse outcome pathway.

245 opics of how TGx approaches could facilitate adverse outcome pathways (AOP) development and enhance r

246 A set of adverse outcome pathways (AOPs) linking inhibition of th

247 ate and allows users to construct predictive adverse outcome pathways (linking chemical-gene molecula

248 Quantitative adverse outcome pathways (qAOPs) describe quantitative r

249 owledge gaps, and develop novel quantitative adverse outcome pathways (qAOPs) for UVB.

250 ptome and provides initial data to construct adverse outcome pathways for skeletal deformities.

251 The concept of Adverse Outcome Pathways is used to illustrate what a ge

252 r initiating events (MIEs) are key events in adverse outcome pathways that link molecular chemistry t

253 s to studying molecular initiating events in adverse outcome pathways.

254 ative identification of patients at risk for adverse outcomes permits treatment modification.

255 ination between those with and those without adverse outcomes (range for area under the receiver oper

256 of the control group utilised, and potential adverse outcomes related to bariatric surgery were not s

257 searched observational studies reporting the adverse outcomes related to LVNC.

258 tial risk factors for developing SSI and the adverse outcomes related to SSI were analysed.

259 hormone (TH) disrupting molecular events and adverse outcomes relevant to aquatic ecological risk ass

260 ond 15 months, although rates of the primary adverse outcomes remained high.

261 It is speculated that these adverse outcomes result from drug-induced activating con

262 ment, make diagnoses, prognoses, and predict adverse outcomes resulting from treatment with certain d

263 d blood pressure (BP) and in doing so reduce adverse outcome risk.

264 rdiac involvement in sarcoidosis may lead to adverse outcomes such as advanced heart block, arrhythmi

265 ease-2019 (COVID-19) and are associated with adverse outcomes such as arrhythmias and death.

266 itous class of chemicals, is associated with adverse outcomes such as pre-eclampsia, low infant birth

267 Analysis of falls with adverse outcomes suggested greater risk in the experienc

268 ostoperative pain is associated with serious adverse outcomes that are costly to patients and society

269 ongitudinal associations between frailty and adverse outcome, the cross-lagged models were explored.

270 e/specific marker to segregate patients with adverse outcomes; therefore, PD-L2 expression was chosen

271 HFpEF and were independently associated with adverse outcomes. These data may help refine risk assess

272 s in pediatric CD identified and prioritized adverse outcomes to be avoided.

273 d molecular targets to downstream events and adverse outcomes traditionally derived from in vivo test

274 associations between biochemical markers and adverse outcomes using logistic and stepwise logistic re

275 Both risk and timing of adverse outcomes vary by subtype.

276 disputed whether women are at excess risk of adverse outcomes versus men after non-ST-segment elevati

277 rom bulk gene expression, we showed that the adverse outcome was correlated with elevated CD8+ T cell

278 Adverse outcome was defined as intensive care unit (ICU)

279 The main outcome termed any adverse outcome was defined as the presence of 1 or more

280 Adverse outcome was detected in the subgroup of patients

281 Risk of other adverse outcomes was also associated with CTS (p < 0.000

282 The risk of adverse outcomes was consistent across proportions of th

283 A lower number of NCB adverse outcomes was observed with rivaroxaban 2.5 mg tw

284 Given these adverse outcomes, we sought to determine the incidence,

285 were observed in some; their odds of having adverse outcomes were 3 to 4 times greater compared to N

286 l discharge and one-year post-disease onset, adverse outcomes were identified in 17.7% and 17.8% of p

287 compared with microcephaly infants, notable adverse outcomes were observed in some; their odds of ha

288 compared to those with microcephaly, notable adverse outcomes were observed in some; their odds of ha

289 Maternal severe adverse outcomes were reported in 24 (5%) of 447 women i

290 were observed in some; their odds of having adverse outcomes were three to four-times greater compar

291 thyroid pathway provides a means of linking adverse outcomes, which may be influenced by many biolog

292 les to trace, track and treat sepsis-related adverse outcomes will be key.

293 M control remained independent predictors of adverse outcome with COVID-19 infection.

294 higher likelihood of experiencing composite adverse outcome with no evidence of interaction (P = .16

295 nancy outcomes, we aimed to reduce all-cause adverse outcomes with community-level interventions targ

296 ication of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the Americ

297 osure differences across gestation comparing adverse outcomes with normal births using mixed-effects

298 lier initiation of delivery reduces maternal adverse outcomes without substantial worsening of neonat

299 ing in significant cardiovascular and kidney adverse outcomes worldwide.

300 ntification of patients at increased risk of adverse outcome would be important, to allow closer obse